Profile data is unavailable for this security.
About the company
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
- Revenue in USD (TTM)269.40m
- Net income in USD-929.79m
- Incorporated1998
- Employees627.00
- LocationMorphoSys AGSemmelweisstr. 7PLANEGG 82152GermanyDEU
- Phone+49 89899270
- Fax+49 8 989927222
- Websitehttps://www.morphosys.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| bluebird bio Inc | 5.14m | -431.14m | 684.44m | 518.00 | -- | 3.47 | -- | 133.13 | -5.77 | -6.96 | 0.069 | 1.92 | 0.0055 | -- | -- | 9,924.71 | -46.37 | -31.45 | -58.80 | -34.64 | -167.19 | 55.94 | -8,386.25 | -2,856.88 | -- | -258.80 | 0.00 | -- | -- | -9.86 | -0.282 | -- | -3.88 | -- |
| Seres Therapeutics Inc | 13.37m | -231.36m | 685.25m | 333.00 | -- | 10.12 | -- | 51.24 | -2.35 | -2.35 | 0.1341 | 0.5432 | 0.0378 | -- | -- | 40,162.16 | -65.34 | -37.60 | -87.02 | -47.14 | -- | -- | -1,729.94 | -151.39 | -- | -82.80 | 0.4294 | -- | 336.33 | 46.11 | 26.42 | -- | -14.95 | -- |
| Poseida Therapeutics Inc | 151.68m | -29.22m | 690.17m | 304.00 | -- | 3.19 | -- | 4.55 | -0.6727 | -0.6727 | 2.29 | 2.52 | 0.4722 | -- | -- | 576,726.30 | -9.10 | -54.94 | -10.40 | -63.47 | -- | -- | -19.26 | -1,184.41 | -- | -6.78 | 0.2119 | -- | -- | 26.18 | 3.70 | -- | 7.80 | -- |
| Emergent Biosolutions Inc | 1.51bn | 53.50m | 696.94m | 2.42k | 17.03 | 0.481 | 3.62 | 0.4605 | 0.8203 | 0.8203 | 29.66 | 29.04 | 0.524 | 1.51 | 6.26 | 626,407.30 | 1.85 | 6.99 | 2.08 | 7.84 | 54.59 | 62.50 | 3.54 | 12.62 | 2.13 | 6.31 | 0.4209 | 0.00 | 15.26 | 29.68 | -24.32 | 29.86 | 24.16 | -- |
| Viking Therapeutics Inc | 0.00 | -61.66m | 697.87m | 17.00 | -- | 4.61 | -- | -- | -0.7993 | -0.7993 | 0.00 | 1.97 | 0.00 | -- | -- | 0.00 | -31.53 | -16.66 | -33.72 | -17.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -39.23 | -- | -- | -- |
| Mersana Therapeutics Inc | 11.90m | -208.27m | 700.41m | 169.00 | -- | 7.67 | -- | 58.84 | -2.43 | -2.43 | 0.1379 | 0.9153 | 0.0447 | -- | -- | 70,437.87 | -78.23 | -52.20 | -104.23 | -70.47 | -- | -- | -1,749.59 | -547.25 | -- | -89.59 | 0.216 | -- | -94.81 | -72.04 | -93.15 | -- | -9.78 | -- |
| Protagonist Therapeutics Inc | 35.20m | -130.11m | 705.01m | 122.00 | -- | 2.89 | -- | 20.03 | -2.67 | -2.67 | 0.7217 | 4.95 | 0.1074 | -- | 13.73 | 298,288.10 | -39.71 | -34.36 | -44.91 | -41.35 | -- | -- | -369.64 | -321.60 | -- | -- | 0.00 | -- | -4.44 | -- | -89.80 | -- | 23.77 | -- |
| Morphosys Ag (ADR) | 269.40m | -929.79m | 709.59m | 627.00 | -- | -- | -- | 2.63 | -6.81 | -6.81 | 1.97 | -0.6806 | 0.0871 | 2.02 | 2.92 | 368,037.80 | -30.05 | -- | -33.50 | -- | 82.88 | -- | -345.13 | -- | 3.67 | -8.87 | 1.35 | -- | -45.19 | -- | -625.55 | -- | -- | -- |
| CTI BioPharma Corp | 32.87m | -112.32m | 714.41m | 121.00 | -- | -- | -- | 21.74 | -1.09 | -1.09 | 0.3074 | -0.1327 | 0.2925 | -- | -- | 271,611.60 | -99.98 | -82.10 | -169.44 | -126.55 | 92.86 | -- | -341.77 | -475.65 | 3.22 | -9.39 | 1.18 | -- | -- | -- | -86.67 | -- | -- | -- |
| Theravance Biopharma Inc | 51.64m | -82.19m | 717.45m | 158.00 | -- | 1.49 | -- | 13.89 | -1.10 | 11.25 | 0.6862 | 7.13 | 0.0885 | -- | 3.67 | 326,854.40 | -14.09 | -50.90 | -17.15 | -62.74 | -- | -- | -159.16 | -439.62 | -- | -- | 0.00 | -- | -23.03 | 2.60 | 28.27 | -- | 9.79 | -- |
| CymaBay Therapeutics Inc | 0.00 | -105.91m | 724.02m | 60.00 | -- | 12.03 | -- | -- | -1.25 | -1.25 | 0.00 | 0.7106 | 0.00 | -- | -- | 0.00 | -75.07 | -45.17 | -82.20 | -49.89 | -- | -- | -- | -3,438.97 | -- | -8.00 | 0.5888 | -- | -- | -- | -76.52 | -- | 15.68 | -- |
| Agenus Inc | 89.90m | -214.70m | 727.73m | 441.00 | -- | -- | -- | 8.09 | -0.7998 | -0.7998 | 0.3333 | -0.0691 | 0.2075 | -- | 5.88 | 203,854.90 | -51.73 | -63.37 | -82.84 | -123.71 | 95.82 | -- | -249.34 | -98.76 | -- | -3.08 | 8.30 | -- | 235.34 | 67.28 | 86.67 | -- | 21.98 | -- |
| Dyne Therapeutics Inc | 0.00 | -181.06m | 729.78m | 115.00 | -- | 2.91 | -- | -- | -3.51 | -3.51 | 0.00 | 4.81 | 0.00 | -- | -- | 0.00 | -47.24 | -- | -50.30 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -151.18 | -- | -- | -- |
| AnaptysBio Inc | 4.49m | -134.85m | 732.97m | 102.00 | -- | 2.63 | -- | 163.24 | -4.83 | -4.83 | 0.1607 | 9.79 | 0.0086 | -- | 4.63 | 44,019.61 | -25.86 | -13.06 | -26.95 | -13.71 | -- | -- | -3,003.32 | -165.53 | -- | -- | 0.00 | -- | -15.77 | 30.51 | -189.98 | -- | 93.77 | -- |
| Merus NV | 45.63m | -63.64m | 732.97m | 121.00 | -- | 2.45 | -- | 16.06 | -1.45 | -1.45 | 1.05 | 6.45 | 0.1184 | -- | 15.56 | 377,099.20 | -16.51 | -24.71 | -20.04 | -29.16 | -- | -- | -139.48 | -178.24 | -- | -- | 0.00 | -- | 64.00 | 77.64 | 21.86 | -- | 9.66 | -- |
| Amneal Pharmaceuticals Inc | 2.14bn | -132.03m | 737.73m | 7.00k | -- | 2.48 | -- | 0.3448 | -0.8749 | -0.8749 | 14.22 | 0.98 | 0.5452 | 2.59 | 3.40 | 305,634.40 | -6.86 | -7.97 | -8.42 | -9.93 | 35.69 | 34.39 | -12.59 | -15.90 | 1.07 | 1.03 | 0.9282 | -- | 5.08 | 20.49 | 156.09 | -- | -0.0996 | -- |
Data as of Feb 03 2023. Currency figures normalised to MorphoSys AG's reporting currency: US Dollar USD
2.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Millennium Management LLCas of 30 Sep 2022 | 953.51k | 0.70% |
| Hudson Bay Capital Management LPas of 30 Sep 2022 | 840.00k | 0.61% |
| Alphacentric Advisors LLCas of 30 Sep 2022 | 185.00k | 0.14% |
| LifeSci Fund Management LLCas of 30 Sep 2022 | 185.00k | 0.14% |
| Morgan Stanley & Co. LLCas of 30 Sep 2022 | 160.43k | 0.12% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2022 | 131.23k | 0.10% |
| Opaleye Management, Inc.as of 30 Sep 2022 | 121.02k | 0.09% |
| Tekla Capital Management LLCas of 30 Sep 2022 | 81.87k | 0.06% |
| Endurant Capital Management LPas of 30 Sep 2022 | 68.29k | 0.05% |
| Candriam Belgium SAas of 30 Sep 2022 | 58.17k | 0.04% |
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
